The drugs dermatologists prescribed for decades to treat eczema and psoriasis may have been targeting the wrong molecular switch all along.

Story Snapshot

  • Mount Sinai researchers discovered HDAC3 protein essential for skin barrier formation works independently of enzyme activity
  • Current HDAC inhibitor drugs target enzyme function, potentially missing HDAC3's unique mechanism in skin conditions
  • Finding challenges decades of treatment approaches for eczema, psoriasis, and cutaneous T-cell lymphoma
  • Discovery opens pathway for developing non-enzymatic HDAC3 modulators as alternative therapies

The Protein That Breaks The Rules

Mount Sinai's 2020 study revealed something dermatology didn't see coming. HDAC3, a protein critical to forming the skin's protective barrier, operates through a mechanism completely different from its molecular cousins HDAC1 and HDAC2. While those proteins rely on enzyme activity to function, HDAC3 regulates skin development independently of enzymatic action. Mice lacking HDAC3 in their epidermis died shortly after birth from dehydration, their skin barrier so compromised they couldn't retain water. The protein orchestrates gene expression by partnering with multiple DNA-binding proteins, creating a regulatory network that standard enzyme-blocking drugs simply cannot reach.

https://www.youtube.com/watch?v=HIVoI2QepP8

Why Current Treatments Miss The Mark

Dr. Sarah E. Millar, who directed the research at Mount Sinai's Black Family Stem Cell Institute, explained the clinical ramifications with clarity. Clinically available HDAC inhibitors block enzyme function exclusively. They effectively target HDAC1 and HDAC2, but they leave HDAC3's unique non-enzymatic mechanism untouched. Patients receiving these drugs for conditions like cutaneous T-cell lymphoma experience treatment effects that mirror HDAC1 and HDAC2 loss, not HDAC3 dysfunction. The pharmaceutical industry spent years developing these inhibitors under the assumption that all HDACs operated through similar mechanisms. That assumption, while reasonable given existing knowledge, turns out to be fundamentally flawed for skin applications.

Breakouts? Let AI guide your skincare plan.

The Barrier That Keeps Us Alive

The skin barrier's importance cannot be overstated. The stratum corneum, your skin's outermost layer, prevents water loss, blocks pathogenic invasion, filters UV radiation, provides mechanical protection, and delivers antioxidant defense. This barrier comprises corneocytes and intercellular lipids derived from keratinocytes through terminal differentiation. When genetic mutations affect proteins like filaggrin or claudin-1, structural weaknesses develop, permeability increases, and conditions like atopic dermatitis emerge. The barrier also maintains acidic pH levels that optimize sphingomyelinase activity, promoting ceramide production essential for barrier repair. TNF signaling increases ceramide production when the barrier suffers disruption, demonstrating the skin's sophisticated self-repair mechanisms.

Free consultation for acne and rosacea.

What This Means For Patients Now

Millions of Americans struggle with eczema, psoriasis, and atopic dermatitis. These conditions stem from barrier dysfunction at the molecular level. The HDAC3 discovery doesn't immediately change prescriptions, but it fundamentally alters the research trajectory. Pharmaceutical companies now face pressure to develop HDAC3-specific modulators that target non-enzymatic functions. Dermatologists gain mechanistic understanding that explains why some patients respond poorly to current HDAC inhibitors. The research team continues investigating how these mechanisms function in pathological conditions, bridging the gap between laboratory findings and clinical applications. Patients deserve treatments designed around accurate biological understanding, not assumptions that proved incomplete.

https://www.youtube.com/watch?v=6YgUkzHPyJw

The Path Forward

Therapeutic innovation takes time, but this discovery accelerates several developments. First, genetic testing for barrier-dysfunction risk factors becomes more valuable when coupled with HDAC3 knowledge. Second, the skincare industry can develop barrier-repair products informed by precise molecular mechanisms rather than trial-and-error formulations. Third, personalized medicine approaches gain traction as clinicians identify which patients would benefit from traditional HDAC inhibitors versus future HDAC3-targeted therapies. The research community recognizes that skin barrier function involves structural, chemical, and immunological systems working together. Lamellar bodies deliver lipids to the stratum corneum, though scientists still don't completely understand the exact mechanisms. These gaps represent opportunities for continued discovery.

Smarter skin care powered by AI.

Sources:

Researchers Identify Mechanisms That Make Skin a Protective Barrier
Skin Barrier Function and Permeability
Researchers Identify Mechanisms That Make Skin a Protective Barrier
The Skin Barrier and Moisturization Function
Frontiers in Medicine: Skin Barrier Mechanisms